Literature DB >> 67464

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study.

N E Miller, D S Thelle, O H Forde, O D Mjos.   

Abstract

The relationship of future clinical coronary heart-disease (C.H.D.) to the plasma-high-density-lipoprotein (H.D.L.)-cholesterol concentration has been examined in a 2-year case-control follow-up study of 6595 men aged 20-49 years living in the municipality of Tromsø, Norway. Measurements were also made of the cholesterol concentration in lower-density (i.e., density less than 1-603 g/ml) lipoproteins, plasma-triglycerides, systolic and diastolic blood-pressures, relative body-weight, and cigarette consumption. Discriminant-function analysis showed that coronary risk was inversely related to H.D.L.-cholesterol concentration and directly related to density less than 1-063 cholesterol. These relationships were independent of each other and of the other measured variables, which showed no significant differences between the cases and controls. H.D.L. cholesterol made a three-fold greater contribution to the prediction of future C.H.D. than did density less than 1-063 cholesterol in this cohort of young men. These findings support the proposal that a low H.D.L. concentration is a common antecedent of clinical C.H.D. and is important in accelerating the progression of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 67464     DOI: 10.1016/s0140-6736(77)92274-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  172 in total

1.  Molecular belt models for the apolipoprotein A-I Paris and Milano mutations.

Authors:  A E Klon; M K Jones; J P Segrest; S C Harvey
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

2.  Lifestyle change and high-density lipoprotein change: the US Department of Veterans Affairs Normative Aging Study.

Authors:  Catherine Rahilly-Tierney; Pantel Vokonas; J Michael Gaziano; Avron Spiro
Journal:  Clin Cardiol       Date:  2012-03-08       Impact factor: 2.882

3.  Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.

Authors:  Urbain Tchoua; Corina Rosales; Daming Tang; Baiba K Gillard; Ashley Vaughan; Hu Yu Lin; Harry S Courtney; Henry J Pownall
Journal:  Lipids       Date:  2010-10-24       Impact factor: 1.880

4.  Association of plasma triglyceride and C-peptide with coronary heart disease in Japanese-American men with a high prevalence of glucose intolerance.

Authors:  R W Bergstrom; D L Leonetti; L L Newell-Morris; W P Shuman; P W Wahl; W Y Fujimoto
Journal:  Diabetologia       Date:  1990-08       Impact factor: 10.122

Review 5.  Plasma lipoproteins, lipid transport, and atherosclerosis: recent developments.

Authors:  N E Miller
Journal:  J Clin Pathol       Date:  1979-07       Impact factor: 3.411

6.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

7.  Quantitation of high density lipoproteins.

Authors:  J J Albers; G R Warnick; M C Chenng
Journal:  Lipids       Date:  1978-12       Impact factor: 1.880

8.  Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry.

Authors:  Matthew T Mazur; Helene L Cardasis; Daniel S Spellman; Andy Liaw; Nathan A Yates; Ronald C Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-13       Impact factor: 11.205

9.  Severity of coronary atherosclerosis related to lipoprotein concentration.

Authors:  P J Jenkins; R W Harper; P J Nestel
Journal:  Br Med J       Date:  1978-08-05

10.  High-density lipoprotein in chronic renal failure and after renal transplantation.

Authors:  E Savdie; J C Gibson; J H Stewart; L A Simons
Journal:  Br Med J       Date:  1979-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.